Over the course of the study, more than 9,000 ID-Cap® System ingestions contributed to a robust assessment of adherence. 84 participants actively used the ID-Cap System for approximately 4 months each. By combining the digital pill data with drug concentrations, the research team was able to accurately quantify tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots (DBS) at each visit according to adherence level¹. Overall, adherence in the study was greater than 90%, and more than 90% of ingestions were detected by the ID-Cap System (as opposed to manually entered)². The study also found that HIV-1 RNA (plasma viral load) remained suppressed (<200 copies/mL) even in cases of intermittent non-adherence, as measured by the ID-Cap System, reinforcing the potential for digital pill technologies in future research on HIV treatment strategies.

This study highlights the growing promise of digital health innovations by both enhancing medication adherence as well as offering critical insights into the effectiveness of ART regimens in real-world settings. 

Nothing in this content constitutes an endorsement by Ryan Coyle or the University of Colorado.

References

1. Coyle RP, Morrow M, Mann SC, Mainella V, Ellis SL, Schwab S, Coppinger C, Barker N, Ellison L, Zheng JH, Al Zuabi S, Alpert PE, Carnes TC, Buffkin DE Jr, Chai PR, Bushman LR, Kiser JJ, MaWhinney S, Brooks KM, Anderson PL, Castillo-Mancilla JR. Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons with HIV Receiving Tenofovir Alafenamide and Emtricitabine-based Antiretroviral Therapy (QUANTI-TAF). Clin Infect Dis. 2024 Nov 22;79(5):1233-1241. doi: 10.1093/cid/ciae212. PMID: 38636950; PMCID: PMC11581703.
2. Coyle RP, Mainella V, Morrow M, Mann SC, Schwab S, Coppinger C, Barker N, Ellis SL, Carnes TC, Alpert PE, Ellison L, Bushman LR, Brooks KM, MaWhinney S, Castillo-Mancilla JR, Anderson PL. Adherence insights from TAF/FTC-based ART co-encapsulated with an ingestible sensor among virologically suppressed persons with HIV. Coyle RP oral presentation: International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs, 2024 Sep 18-19; Liverpool, UK. Br J Clin Pharmacol, 90: 10-11. https://doi.org/10.1111/bcp.16291.

The post Recap with ID-Cap®: Monitoring HIV Medication Adherence in University of Colorado’s QUANTI-TAF Study first appeared on etectRx.

The ID-Cap System embarks on a promising journey in 2024, receiving continued praise from clinical trials.

The momentum of medication adherence carried into the new year, with four esteemed researchers—Edward Boyer, MD (OSU), Peter Chai, MD (BW), Jasper Lee, Ph.D (BW) and Georgia Goodman, BS (BW)—taking the stage at HICSS, the worldwide longest standing scientific conference in IT Management. All four researchers shared compelling insights into the success of etectRx’s digital pill solution, particularly in studies focused on HIV and PrEP medication adherence using the FDA cleared ID-Cap System.

This significant event showcased results from four distinct clinical trials utilizing the ID-Cap System, highlighting its effectiveness in promoting adherence to medication in populations where adherence is of utmost importance. The researchers’ presentations underscored the positive impact of digital innovation in healthcare.

Established in 1968, the Hawaii International Conference on System Sciences (HICSS) stands as one of the most impactful scientific conferences in Information Technology Management globally. This well known conference brings together scholars from academia and industry professionals from over 60 countries, HICSS provides a dynamic platform for the exchange of ideas in various areas of information, computer, and system sciences. The event continues to foster collaboration and innovation in the ever-evolving landscape of technology and its contributions to healthcare.

Continue below to read the full research study results presented at HICSS 2024.

Preliminary Qualitative Data From MyTPill Study

Real-World Implementation Challenges Associated With a Digital Pill System to Measure Adherence to HIV Pre-Exposure Prophylaxis From Two Studies of Men Who Have Sex With Men

Tough Pill to Swallow? Preliminary Attitudes Toward the Digital Pill System Among Pregnant and Postpartum People With HIV in South Africa

The post ALOHA! Adherence: ID-Cap™ Clinical Trial Research Presented at the 2024 Hawaii International Conference on System Sciences (HICSS) first appeared on etectRx.

The development of a Wrist-Worn Reader is the latest advancement to the ID-Cap System, offering a promising solution to address the complex issue of medication non-adherence.

While the previous ID-Cap component design employed a wearable Reader in the form of a necklace, the evolution of the Wrist-Worn Reader provides a more functional and convenient solution. The Wrist-Worn Reader aims to revolutionize the ID-Cap System component capabilities by catering to different user preferences and lifestyles, making medication adherence technology more adaptable into everyday life. Preliminary testing results of the Wrist-Worn Reader showcase promising results for innovative technology to improve medication adherence and patient care. Read more on the National Institutes of Health (NIH) funded HIV PrEP study here.

The post ID Cap™ System Evolution: Introducing the Wrist-Worn Reader first appeared on etectRx.

University of Cape Town announces ID-Cap System acceptability study in South Africa.

The post Global Growth: University of Cape Town Announces ID-Cap™ System Acceptability Study first appeared on etectRx.

etectRx announces record-breaking use of the ID-Cap System, utilized in University of Colorado’s HIV treatment study.

A seamless, end-to-end solution, the ID-Cap is the only ingestible sensor solution which allowed the study’s researchers to monitor, track, trend, report, and provide real-time, accurate data through etectRx’s core technology, eBurst. When nonadherence was detected by the ingestible sensor technology, University of Colorado researchers were able to intervene in a timely fashion to send real-time dosing reminders to patients’ smartphone apps.

QUANTI-TAF began in August 2020, and the last follow-up concluded in May 2023. A total of 84 participants were enrolled in the study for up to 4 months each, resulting in 8,910 expected ingestions over 9,049 days monitored, and a cumulative adherence rate of 95%. The QUANTI-TAF study showed consistently high acceptability of the ID-Cap System over time, as participants used it for up to approximately 112 days (4 months).

Data from University of Colorado’s QUANTI-TAF study demonstrates significant milestones for the ID-Cap System with a reputation for demonstrating strong results and providing data to accurately track patients’ adherence to their oral medications. “The ID-Cap System was central to our QUANTI-TAF study; we used the digital pill data to establish adherence benchmarks for our drug concentrations, which was a key outcome of our study,” said Peter Anderson, PharmD- Antiviral Pharmacology, Professor at University of Colorado Anshutz Medical Campus.

etectRx gained FDA clearance for its innovative ID-Cap System technology in December 2019. Since FDA clearance, the technology has generated strong, accurate results across multiple indications, particularly with patient populations with traditionally poor levels of medication adherence, including those with substance abuse disorders.

About etectRx

etectRx is a digital health company. The FDA-cleared ID-Cap System uniquely addresses the issue with adherence to (oral) medication. The accurate, flexible, and simple digital pill system allows researchers, pharmacists, physicians, and pharmaceutical companies to rethink approaches to medication adherence, innovate with confidence, and accelerate patient outcomes. To learn more, visit https://etectrx.com/.

The post ID-Cap™ System Powers Historic HIV Digital Pill Study first appeared on etectRx.

The post Preliminary Analysis of Real-Time Therapy-Based Interventions with ID-Cap™ System Demonstrates Effectiveness of Maintaining Adherence for High-Risk Populations first appeared on etectRx.

The post High Patient Engagement with the ID-Cap™ System on 98.0% of Use-Days in a Clinical Study During the COVID-19 Pandemic first appeared on etectRx.

Unlike the RPM codes, RTM services are available to Qualified Health Care Practitioners (“QHCPs”) who are not able to independently order and bill for E/M services. RTM is in an evolving state of development. In the near future, we can expect CMS will broaden its RTM coverage beyond musculoskeletal and respiratory disorders. In addition, as with most other CMS payment policy once there is significant RTM activity private insurers will adopt coverage for these services.

The post Remote Therapy Monitoring Billing Guide first appeared on etectRx.

The post Leading Digital Pill Solution Surpasses 10,000 Ingestions first appeared on etectRx.

The post Formative Acceptance of Ingestible Biosensors to Measure Adherence to TB Medications first appeared on etectRx.